Piramal Pharma (NSE:PPLPHARMA) Debt-to-Revenue : 0.46 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Piramal Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹21,084 Mil. Piramal Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹26,017 Mil. Piramal Pharma's annualized Revenue for the quarter that ended in Mar. 2024 was ₹102,094 Mil. Piramal Pharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.46.

Piramal Pharma Debt-to-Revenue Historical Data

The historical data trend for Piramal Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Debt-to-Revenue Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Debt-to-Revenue

0.06

0.64

0.80

0.58

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial							0.65	-	0.59	-	0.46

Competitive Comparison of Piramal Pharma's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Piramal Pharma's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's Debt-to-Revenue falls into.

Piramal Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Piramal Pharma's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(21084.2	+	26017.4)	/	81711.6
	=	0.58

Piramal Pharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(21084.2	+	26017.4)	/	102094.4
	=	0.46

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Piramal Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma (NSE:PPLPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Debt-to-Revenue

Traded in Other Exchanges

543635:India

Address

Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramal.com

Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Piramal Pharma (NSE:PPLPHARMA) Headlines

No Headlines